CTLA4 and pancreatitis: Matching the finding from some current literature, where immune related hepatitis, pancreatitis, pneumonitis, and nephritis frequently recurred upon rechallenge with PD1 inhibitors in patients who previously experienced severe irAEs with dual PD-1 and CTLA-4 blockade (121).